» Valbiotis signs a research partnership in the intestinal microbiota with the University of Clermont Auvergne MyPharma Editions

Posted on Thursday, December 15, 2022

Valbiotis, a Research and Development company committed to scientific innovation for the prevention and fight against metabolic and cardiovascular diseases, announces the signature of a research partnership in the intestinal microbiota with the MEDIS2 Unit of Clermont University Auvergne on its active substances TOTUM•070 and TOTUM•448 against dyslipidemia and metabolic damage to the liver, partly funded by the National Research Agency.

Led by a joint laboratory for both entities, the MIMETiv project will aim to develop a complete and dynamic human gastrointestinal model integrating the microbiota of the small intestine for the first time. This model will make it possible to obtain exclusive data on the effects and modes of action of the active plant substances of Valbiotis at the intestinal level, within the framework of non-drug strategies for the fight against metabolic and cardiovascular diseases.

Pascal SIRVENT, Director of Discovery, Preclinical and Translational Research, and member of the Management Board of Valbiotis declares: “In terms of research and development, our public-private partnership strategy is based on collaborations with high scientific added value. The in vitro digestive model project carried out by the MEDIS Unit is a unique innovation in terms of research on human digestion, which we have been following for a long time and to which we are very happy to contribute within this new joint laboratory. As an industrial player, the MIMETiv project represents for us a very promising lever to approach cardiovascular and metabolic diseases from the digestive and intestinal prism, with particular attention to the intestinal microbiota. It’s an innovative angle, in line with our research and development strategy. At the end of this project, we should obtain exclusive data for our active substances in two of our key indications: dyslipidemia and metabolic damage to the liver. »

• The MIMETiv1 research project, which will focus on the active substances TOTUM•070 and TOTUM•448 developed by Valbiotis, will be carried out by a joint laboratory, partly funded by the National Research Agency (ANR) to the tune of 363,000 €.

• This work will make it possible to develop, by 2024, the most complete model of the human upper digestive tract in the world, integrating in particular the microbiota of the small intestine.

• The expected results will support the non-drug strategies against metabolic and cardiovascular diseases developed by Valbiotis, in particular the herbal active substances TOTUM•070 and TOTUM•448.

• The MIMETiv project will provide exclusive data on the metabolites, bioavailability, mode of action at the intestinal level and effects on the human microbiota of these two active substances.

Stéphanie BLANQUET-DIOT, Teacher-Researcher and Deputy Director of MEDIS, comments: “This in vitro digestive system is unique in the number of parameters reproduced compared to in vivo digestion in humans, such as body temperature, kinetics pH in the stomach and small intestine, gastrointestinal transit time, differential gastric emptying between liquids and solid particles, salivary, gastric, biliary and pancreatic secretions, absorption of water and digestive products, the progressive anaerobiosis along the digestive tract and the microbiota at the level of the compartments reproducing the small intestine. »

Dyslipidemia and metabolic damage to the liver (NAFL, NASH), indications for the active substances TOTUM•070 and TOTUM•448 respectively, are highly prevalent diseases, precursors of pathologies involving the vital prognosis of patients (atherosclerosis, cirrhosis). Their complex physiopathology includes, among other things, alterations in carbohydrate and/or lipid metabolism, digestive abnormalities and disturbances of the intestinal microbiota, all phenomena that the MIMETiv project will make it possible to approach in humans in an integrated way. Among the main innovations, MIMETiv should provide access to the microbiota of the small intestine, the major site of digestion and absorption of dietary carbohydrates and lipids in humans. To date, data linking metabolic diseases and intestinal microbiota have mainly been obtained by stool analysis, which partially reflects the microbiota of the colon (large intestine).

The MIMETiv project: an exclusive tool for R&D on metabolic and cardiovascular diseases

The MIMETiv project, which will benefit from the combined expertise of the MEDIS Unit and Valbiotis, will take place in two stages.

The first should lead in 2024 to the design of the most complete model in the world of the human digestive environment, based on the in vitro simulation work carried out over a long period of time by the MEDIS Unit. The work will consist of optimizing the ESIN (Engineered Stomach and Small Intestine) system, developed by MEDIS, by improving its performance and integrating the human microbiota into key compartments of the digestive tract such as the small intestine.

Once validated, this model will constitute an exclusive tool for the evaluation of active plant substances of Valbiotis in the human digestive environment. The explorations carried out will cover a complete set of R&D objectives for two active substances, TOTUM•070 and TOTUM•448:

• metabolomic analysis, to identify the metabolites of these active substances and specify their bioavailability in the various gastrointestinal compartments;

• analysis of modes of action, to assess their effects on digestion and intestinal absorption
fats and carbohydrates;

• analysis of the intestinal microbiota, to assess their impact on the dysbioses associated with the diseases
metabolic;

• analysis of the hepatic metabolic pathways, thanks to the original coupling of ESIN with hepatic cells in culture, to assess their possible modulation by the active substances of Valbiotis.

The Management Committee of the joint MIMETiv laboratory is made up of 5 members. It is co-directed by Stéphanie BLANQUET-DIOT, Deputy Director of MEDIS, responsible for the digestive environment simulation platform, with strong expertise in microbiology and intestinal microbiota, in vitro digestion, digestive physiology and nutrition, and Pascal SIRVENT, Director of Discovery, Preclinical and Translational Research, and member of the Management Board of Valbiotis. He is responsible for Riom’s R&D platform, with strong expertise in metabolic diseases and the development of plant-based health products.

__________________________

1MIMETiv: Intestinal microbiota and metabolic diseases in humans: a unique in vitro digestive system to catalyze the development of innovative nutritional strategies. LabCom Scientific document

2The MEDIS Unit (Digestive Environment and Health Microbiology) is a Joint Research Unit between INRAE ​​(National Research Institute for Agriculture, Food and the Environment) and UCA (Clermont Auvergne University) created in January 2017 .

Source and visual: Valbiotis

We would love to give thanks to the author of this short article for this incredible web content

» Valbiotis signs a research partnership in the intestinal microbiota with the University of Clermont Auvergne MyPharma Editions


Check out our social media accounts along with other pages related to themhttps://www.ai-magazine.com/related-pages/